Development of abuse-deterrent nanotechnology formulation for effective pain management

阿尔图斯配方公司专注于药物输送技术的开发，以生产具有成本效益的“安全使用”产品，以改善患者的生活。Altus开发了一系列创新的两亲性和pH敏感型嵌段共聚物，可以在水介质中自组装形成纳米尺寸的嵌段共聚物胶束(BCMS)，将药物包裹在其核心内，并使药物能够传递。这一专利系列嵌段共聚物包括形成胶束外壳的聚乙二醇亲水嵌段，以及由聚甲基丙烯酸酯和聚(甲基丙烯酸叔丁酯)(缩写为：PMA)随机共聚物组成的成核药物捕获嵌段。PMA核心形成块的性质是，它以非晶体形式保留药物，并在通过胃的运输过程中保护它；由于其对pH的敏感性，PMA块允许药物在药物吸收最大的小肠中一次定点释放。为此，Altus已经进行了临床前研究，证明了在口服后，聚乙二醇b-聚甲基丙烯酸甲酯共聚胶束能够有效地输送疏水性抗癌药物。Altus现在有兴趣扩大这一前景看好的系列材料的使用，以创造作为口服控释液体的活性物质的专利配方，以有效地控制疼痛。

Altus Formulation Inc. is focused on the development of drug delivery technologies to generate cost effective 'safe to use' products to improve the lives of patients. Altus has developed an innovative series of amphiphilic and pH-sensitive block copolymers that can self-assemble in aqueous media to form nano-sized block copolymer micelles (BCMs) that entrap drugs within their cores and enable drug delivery. This proprietary series of block copolymers includes a poly(ethylene glycol) (PEG) hydrophilic block that forms the outer shell of the micelles and a core-forming, drug trapping block that is comprised of a random copolymer of polymethacrylate and poly(t-butyl methacrylate) (abbreviated: PMA). The nature of the PMA core-forming block is such that it retains the drug in a non-crystalline form and protects it during transit through the stomach; due to its pH sensitivity the PMA block allows site-specific release of the drug once in the small intestine where drug absorption is maximized. To this point, Altus has conducted pre-clinical studies demonstrating the ability of PEG-b-PMA copolymer micelles to effectively deliver hydrophobic anti-cancer drugs following oral administration. Altus is now interested in expanding the use of this promising series of materials to create proprietary formulations of active agents as oral controlled release liquids for effective pain management.